sofosbuvir/ledipasvir方案治疗HCV 6a型慢性丙型肝炎的临床效果和安全性

李威; 康谊; 丁岗强; 尚佳; 周元平

doi:10.3969/j.issn.1001-5256.2019.03.015

sofosbuvir/ledipasvir方案治疗HCV 6a型慢性丙型肝炎的临床效果和安全性

DOI: 10.3969/j.issn.1001-5256.2019.03.015

1. 河南省人民医院感染科
2. 南方医科大学南方医院感染内科

基金项目:

国家自然科学基金资助项目(81470856)；河南省科技攻关计划项目(162102310030)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 1632
- HTML全文浏览量: 11
- PDF下载量: 913
- 被引次数: 14
出版历程
- 收稿日期: 2018-11-30
- 出版日期: 2019-03-20

Clinical effect and safety of sofosbuvir-ledipasvir regimen in treatment of patients with HCV genotype 6a chronic hepatitis C

Department of Infectious Diseases, Henan Provincial People's Hospital

Research funding:

摘要

摘要: 目的探讨sofosbuvir/ledipasvir（SOF+LDV）治疗HCV 6a型慢性丙型肝炎的效果和安全性。方法本研究为前瞻性观察研究,纳入2014年10月到2016年12月在河南省人民医院及南方医院感染科就诊的63例HCV 6a型慢性丙型肝炎患者。将所纳入患者分为2组,分别给予SOF+LDV 12周、PEG-IFN联合利巴韦林（PR） 24周抗病毒治疗。在治疗期间及治疗终止后随访检测HCV RNA,评价病毒学应答。计数资料2组间比较采用χ2检验;计量资料2组间比较采用Mann-Whitney U检验。结果 PR组和SOF+LDV组患者的快速病毒学应答率（85. 3%vs 100%）、治疗结束时病毒学应答率（94. 1%vs 100%）差异均无统计学意义（P值均> 0. 05）。SOF+LDV组持续病毒学应答率为96. 4%,显著高于PR组的73. 5%（χ2=4. 38,P=0. 036）。PR组总体不良反应发生率明显高于SOF+LDV组（χ2=7. 54,P=0. 006）。SOF+LDV组后续随访有1例肝硬化患者发生小肝癌。而PR组至随访截止时间无1例患者发生肝癌。结...
- 肝炎,丙型,慢性 /
- 基因型 /
- 持续病毒学应答 /
- 治疗结果
Abstract: Objective To investigate the clinical effect and safety of sofosbuvir ( SOF) -ledipasvir ( LDV) in the treatment of patients withHCV genotype 6 a chronic hepatitis C ( CHC) . Methods A total of 63 patients with HCV genotype 6 a CHC who visited Department of In-fectious Diseases, Henan Provincial People's Hospital and Nanfang Hospital, from October 2014 to December 2016 were enrolled in thisprospective observational study. They were divided into SOF-LDV group ( treated with SOF-LDV for 12 weeks) and PR group ( treatedwith pegylated interferon combined with ribavirin for 24 weeks) . HCV RNA was measured during treatment and follow-up, and virologicresponse was evaluated. The chi-square test was used for comparison of categorical data between two groups, and the Mann-Whitney Utest was used for comparison of continuous data between two groups. Results There were no significant differences between the PR groupand the SOF-LDV group in rapid virologic response rate ( 85. 3% vs 100%, P > 0. 05) and virologic response rate at the end of treatment ( 94. 1% vs 100%, P > 0. 05) . The SOF-LDV group had a significantly higher sustained virologic response rate than the PR group ( 96.4% vs 73. 5%, χ2= 4. 38, P = 0. 036) . The PR group had a significantly higher incidence rate of adverse events than the SOF-LDV group ( χ2= 7. 54, P = 0. 006) . During follow-up, one patient with liver cirrhosis in the SOF-LDV group developed small hepatocellular carcino-ma, while no patient in the PR group developed liver cancer at the end of follow-up. Conclusion SOF-LDV for 12 weeks is safe and ef-fective in the treatment of HCV genotype 6 a CHC, but liver cancer should be closely monitored in patients with liver cirrhosis.
- hepatitis C, chronic /
- genotype /
- sustained virological response /
- treatment outcome

HTML全文

参考文献(16)

[1] CONTI F, BUONFIGLIOLI F, SCUTERI A, et al. Early occur-rence and recurrence of hepatocellular carcinoma in HCV-re-lated cirrhosis treated with direct-acting antivirals[J]. J Hep-atol, 2016, 65 (4) :727-733.

[2] NAGATA H, NAKAGAWA M, ASAHINA Y, et al. Effect of in-terferon-based and-free therapy on early occurrence andrecurrence of hepatocellular carcinoma in chronic hepatitis C[J]. J Hepatol, 2017, 67 (5) :933-939.

[3] ZENG QL, XU GH, ZHANG JY, et al. Generic ledipasvir-so-fosbuvir for patients with chronic hepatitis C:A real-life ob-servational study[J]. J Hepatol, 2017, 66 (6) :1123-1129.

[4] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association. The guideline ofprevention and treatment for hepatitis C:A 2015 update[J]. JCIin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[5] LI W, NING HB, KANG Y, et al. Impact of directly sequencedcore and non-structrural protein 5B regions on hepatitis C vi-rus genotyping[J]. Chin J Infect Dis, 2015, 33 (6) :343-345. (in Chinese) 李威, 宁会彬, 康谊, 等.核心蛋白和非结构蛋白5B直接测序法对丙型肝炎病毒基因分型的影响[J].中华传染病杂志, 2015, 33 (6) :343-345.

[6] LI W, ZENG Y, WANG J, et al. Predicting sustained viral re-sponse to hepatitis C using a rapid and simple IL28Brs8099917 genotyping assay[J]. Antiviral Res, 2012, 94 (1) :54-56.

[7] SETO WK, LAI CL, FUNG J, et al. Natural history of chronichepatitis C:Genotype 1 versus genotype 6[J]. J Hepatol, 2010, 53 (3) :444-448.

[8] LU L, NAKANO T, HE Y, et al. Hepatitis C virus genotype dis-tribution in China:Predominance of closely related subtype 1bisolates and existence of new genotype 6 variants[J]. J MedVirol, 2005, 75 (4) :538-549.

[9] WEI JF, ZHANG TS, HUANG HH, et al. A novel method forhepatitis C virus genotyping using RT-PCR reverse dot blothybridizationte chnique[J]. J South Med Univ, 2010, 30 (10) :2270-2272, 2276. (in Chinese) 魏君锋, 张太松, 黄辉红, 等.反向点杂交法检测广东地区丙型肝炎病毒基因型和基因亚型[J].南方医科大学学报, 2010, 30 (10) :2270-2272, 2276.

[10] ZHOU Y, WANG X, MAO Q, et al. Changes in modes of hep-atitis C infection acquisition and genotypes in southwest China[J]. J Clin Virol, 2009, 46 (3) :230-233.

[11] RAO H, WEI L, LOPEZ-TALAVERA JC, et al. Distributionand clinical correlates of viral and host genotypes in Chinesepatients with chronic hepatitis C virus infection[J]. J Gastro-enterol Hepatol, 2015, 29 (3) :545-553.

[12] CUI WG, XUE XJ, LIU CH, et al. Epidemiological survey onthe hepatitis C virus and its genotyping analysis in Henan prov-ince in 2012[J]. Clin J Prev Med, 2013, 47 (6) :518-522. (in Chinese) 崔为国, 薛秀娟, 刘春华, 等. 2012年河南省丙型肝炎病毒感染状况及基因型分布调查[J].中华预防医学杂志, 2013, 47 (6) :518-522.

[13] LI W, XI L, CAI Q, et al. Changes in the distribution of hepati-tis C virus genotypes and their association with shifts in trans-mission routes in Henan, China[J]. J Public Health, 2018, 26 (2) :157-162.

[14] ESTEBAN JI, SAULEDA S, QUER J. The changing epidemiol-ogy of hepatitis C virus infection in Europe[J]. J Hepatol, 2008, 48 (1) :148-162.

[15] ZHOU YQ, WANG XH, HONG GH, et al. Twenty-four weeksof pegylated interferon plus ribavirin effectively treat patientswith HCV genotype 6a[J]. J Viral Hepat, 2011, 18 (8) :595-600.

[16] WANG Q, LUO BF, WEl L. A risk assessment of disease pro-gression after virus elimination with ch ronic hepatitis C[J]. JClin Hepatol, 2018, 34 (2) :227-228. (in Chinese) 王琴, 罗碧芬, 魏来.慢性丙型肝炎清除病毒后疾病进展风险评估[J].临床肝胆病杂志, 2018, 34 (2) :227-228.

施引文献

期刊类型引用(13)

1.	乔旭东，朱照，骆瑞闯，王玲. 肝脏超声剪切波弹性成像在乙肝肝硬化患者肝纤维化程度评估中的应用价值. 中国现代医学杂志. 2025(05): 60-65 . 百度学术
2.	梁静，刘继青，陈军，王珊珊，刘芳. 瞬时弹性成像技术联合瘦素对妊娠期急性脂肪肝患者的诊断价值. 中国妇幼保健. 2023(05): 942-945 . 百度学术
3.	李瑞，刘华胜，陈颖. 鉴别原发性骨髓纤维化与肝硬化相关门脉高压的最新研究进展. 中国实验血液学杂志. 2023(02): 598-601 . 百度学术
4.	张冲. 超声瞬时弹性成像技术在早期肝硬化诊断中应用价值的研究. 中国医疗器械信息. 2023(06): 112-114 . 百度学术
5.	张喆，李民，赵丽琴，刘长春，黄旭方，曹邱婷，王麟，贾继东. 基于CT影像组学特征评估肝硬化患者肝脏储备功能. CT理论与应用研究. 2022(01): 55-62 . 百度学术
6.	顾达，童聪，赵祥安，向晓星. 肝硬化食管胃静脉曲张再出血相关因素研究进展. 世界华人消化杂志. 2022(05): 230-234 . 百度学术
7.	黄帅钦，侯循亚，管洁，丁国建，陈鸿志，邓维成，吴翔. Baveno指标在门静脉高压出血风险筛查中的研究进展及其在晚期血吸虫病中的应用前景分析. 实用预防医学. 2022(11): 1405-1409 . 百度学术
8.	黄义华，黄平兰，黄菊玲，江新华，袁航，毛卫. C反应蛋白/前清蛋白比值结合终末期肝病模型评分对脾切除术后门静脉系统血栓的预测价值. 中国当代医药. 2022(33): 59-61+65 . 百度学术
9.	陈逸云，郑玥琪，时桢，谢婵，周峰峰，陈建杰，唐苾芯. 加味茵陈蒿汤对UDCA应答不佳的原发性胆汁性胆管炎患者肝纤维化的影响. 上海中医药大学学报. 2021(03): 28-32 . 百度学术
10.	王佳强，薛红红，白宝艳，李倩. 瞬时弹性成像技术对射频消融治疗肝细胞癌患者的疗效观察. 中国肿瘤临床与康复. 2021(06): 644-647 . 百度学术
11.	张争运，杨梅，刘百庆，马奔，夏文中. 肝硬化患者食管胃底静脉曲张无创预测模型的构建及验证. 重庆医学. 2021(21): 3669-3673+3677 . 百度学术
12.	徐卓艺. 瞬时弹性成像技术在肝纤维化及脂肪肝诊断中的作用. 包头医学院学报. 2020(08): 28-31 . 百度学术
13.	曾凡森，杨花梅，龚余，佘兰辉，李旭芳，徐翼. 瞬时弹性成像对肥胖儿童肝脏特征的评估价值. 中华医学杂志. 2020(40): 3164-3168 . 百度学术